The research in my laboratory aims to understand the regulation of the signal transduction pathways related to tumorigenesis, through the development of methods that can provide quantitative information about the complex interactions of such pathways in real time in a single cell. We have developed the first live-cell biosensor for monitoring activity on cancer targets such as cyclin-dependent kinases in tumours. In addition, we are working with biopharmaceutical and biotech companies on the development of novel drugs against cancer and cardiac hypertrophy and novel nanobiotechnology tools to study molecular interactions.
We are collaborating and publishing joint papers with a number of research institutions including: Harvard Medical School, University of Edinburgh, A* STAR Singapore, University of Namur, University of Liege, Medical University Sofia, Medical University Plovdiv, Technical University Varna, Sofia University, Trakia University, University of Dundee, The Roslin Institute and Royal School of Veterinary Sudies, St James’s University Hospital Leeds, Howard Hughes Medical Institute, Novartis Institutes for Biomedical Research and Dana-Farber Cancer Institute. We are also working with industrial partners namely: Cyclacel Pharmaceuticals Inc., Scientific Technological Service (STS) Ltd. and Norton Scientific Inc.
Module title: Industrial/Biomedical Biotechnology (BI1103) – for MSc
Module title: Industrial/Biomedical Biotechnology (BI1104) – for BSc
Module title: Professional Studies (BI0704A)
Module title: Adult Nursing (HE0808A)
Module title: Human Biology 3 (HE0852A)
Module title: Systems Biology in Biomedicine (BI1013A)
Module title: Clinical Biochemistry and Cellular Pathology (HS0905A)
Module title: Techniques and Skills (BI0703A)
Module title: Project Skills (BI1009A)
Module title: BMS Honours Projects (BI1008A)
Module title: Principles of biology (BI0701A)
Books and books chapters:
Trifonov D., Zhelev N. Drug discovery and development. In Current applications of biotechnology (M Dundar ed) 2015,Erciyes University , p 273
Bown J., Deeni Y., Goltsov A., Khalil H., Isaacs J., Li Y., Sampson A.T., Savage A., Zhelev N. Cancer systems biology: integrating experimental and theoretical systems at cellular and tissue scales. In Current applications of biotechnology (M Dundar ed) 2015,Erciyes University , p 357
Zhelev N., Trifonov D., Wang S., Hassan M., El Serafi I., Mitev V. Seliciclib – discovery and development. 2015, DSP, Dundee, Edinburgh, London
Khalil H.S, Chakarov S., Zhelev N. ATM - a damage sensor and cancer target. 2014, DSP, Dundee, Edinburgh, London
Chakarov S., Petkova R., Russev G. Zhelev N. DNA repair and individual repair capacity. 2014, DSP, Dundee, Edinburgh, London
White R., Zhelev N., Bradley D. Issues of Innovation, Design and Development in Relation to the Implementation of Light Scattering Instrumentation. In Mechatronics and manufacturing engineering (J.P. Davim ed.) 2012, Woodhead Publishing, Cambridge, p 1
Vlaykova T., Gulubova M., Yovchev Y., Dimov D., Vlaykova D., Chilingirov P., Zhelev N. Glutathione-S-transferases in development, progression and therapy of colorectal cancer In Colorectal Cancer / Book 1. 2011, Intech Open Access Publisher, Rijeka p 81
Todorov, I.T., Zhelev N.Zh., Philipova, R.N., Hadjiolov, A.A. 1990 Synthesis and phosphorylation of the 125 kDa nuclear matrix protein mitotin during the cell cycle. In Nuclear structure and function (I.B.Zbarsky and J.R.Harris, eds), Plenum London, p 323.
Research Articles and Patents (granted):
Lewis K, Reynolds L, Kuzmanova E, Zhelev N. Evaluation of the therapeutic potential of a CDK9-inhibiting compound in human hypertrophic cardiomyopathy using hESC-derived cardiomyocytes. J Biotechnol Biomater 2015; vol 5(2) p 64
Khalil HS, Mitev V, Vlaykoya T, Cayicchi L, Zhelev N. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol 2015 vol 202 p 40
Zhelev N. Novel stem-cell-based approaches in the development of cyclein-dependent kinase inhibitors as new therapeutics in cardiology. J Biotechnol Biomater 2015; vol 5(2) p 32
Chakarov S, Petkova R, Russev GCh, Zhelev N. DNA damage and the circadian clock. Biodiscovery 2014; vol 13, 1
Bown JL., Idowu MA., Khalil HS, Goltsov A., Deeni Y., Zhelev N., Langdon SP., Harrison DJ. Process-based vs. data-driven modelling of cancer cell behavior. J Biotechnol 2014 vol 185 p13
Chakarov S, Petkova R, Russev GCh, Zhelev N. DNA repair and carcinogenesis. Biodiscovery 2014; vol 12, 1
Zhelev N, Oluwaseun O.A., Uth K, D' Ascanio I., Stoyanova V., Vlaykova t., Mitev V. Systems biology approach in the discovery and development of cyclin-dependent kinase inhibitors as new therapeutics in oncology and cardiology. J Biotechnol Biomater 2014, vol. 3(5) p 81
Chakarov S, Petkova R, Russev GCh, Zhelev N. DNA damage and mutation. Types of DNA damage. Biodiscovery 2014; vol 11, 1
Zhelev N., Tupone MG., Cecceroni L., Cavicchi L., D’Ascanio I., Khalil HS., Uth K., Mitev V. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol 2014 vol 185 p10
Zhelev N., Trifonov D., Wang S., Hassan M., El Serafi I., Mitev V. From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development. Biodiscovery 2013 vol 10, 1.
Zhelev N., Tummala H., Trifonov D., D' Ascanio I., Oluwaseun O.A., Fischer P.M. Recent advances in the development of cyclin-dependent kinase inhibitors as new therapeutics in oncology and cardiology. Curr Opin Biotech 2013 vol 24(1) p 25
Khalil HS., Idowu M., Bown J., Zhelev N. Reverse engineering of drug induced DNA damage response signalling pathway reveals dual outcomes of ATM kinase inhibition. Biodiscovery 2013 vol 9, 4
Khalil H.S., Tummala H., DeCaris L., Zhelev N. Pharmacological inhibition of ATM results in mitochondrial biogenesis in AMPK independent manner. Cancer Res 2013 vol 73(8) p 1697
Zhelev N., Khalil HS., White R. New approaches to rapid screening for protein aggregates by light scattering. Biotechnol & Biotechnol Eq. 2013 vol 27(6), 4327.
Chelenkova P., Petkova R., D' Ascanio I., Zhelev N., Chakarov S. In sickness and in health: a set of markers for individual repair capacity in risk assessment, monitoring and prognosis of human disease. Curr Opin Biotech 2013 vol 24(1) p 105
Tummala H., Khalil HS., Islam R., Jones SJ., Ellis IR., D’Ascanio I., Zhelev N., Lester DH. The alternate GNB3 splice variant, Gβ3s, exhibits an altered signalling response to EGF stimulation, which leads to enhanced cell migration. Biodiscovery 2013 vol 9, 3.
Trifonov D, Tummala H., Clements S., Zhelev N. Effect of roscovitine on cardiac hypertrophy in human stem cell derived cardiomyocytes. Curr Opin Biotech 2013 vol 24(1) p 114.
Khalil H.S., Tummala H., Zhelev N. ATM in focus: A damage sensor and cancer target. Biodiscovery 2012 vol 5, 1
Tummala H., Khalil H.S., Mitev V., Zhelev N, A quantitative integrated systems biology approach for modeling cell cycle pathways in normal and tumor cells. Cancer Res 2012 vol 72(8) p 4913
Khalil, H.S., Tummala H., Zhelev N. Phosphorylated ATM at S-1981 (pATM) undergoes COPI mediated Golgi export upon DNA damage. FEBS J 2012 vol 279(S1) p 146
Tummala H, Khalil HS, Mitev V, Zhelev N, A quantitative integrated systems biology approach for modeling cell cycle pathways in normal and tumor cells. Cancer Res 2012 vol 72(8) p 4913
Khalil H.S., Tummala H., Chakarov S,. Zhelev N., Lane D.P. Targeting ATM pathway for therapeutic intervention in cancer. Biodiscovery 2012 vol 1, 3
Khalil, HS, Tummala H, Zhelev N. Differences in the DDR enzymes activation kinetics between normal and cancer cells could be utilized to achieve targeted cellular sensitivity towards genotoxic agents. Cancer Res 2012 vol 72(8) p 3103
Khalil, HS, Tummala H, Zhelev N. Phosphorylated ATM at S-1981 (pATM) undergoes COPI mediated Golgi export upon DNA damage. FEBS J 2012 vol 279(S1) p 146
Tummala H, Khalil HS, DAscanio I, Wehner D, Lester DH, Babraj J, Zhelev N. Human 825C>T polymorphism in GNB3 gene promotes enhanced cell migration by inducing cytosolic calcium influx and hyper phosphorylation of ERK regulated mTOR pathway. FEBS J 2012 vol 279(S1) p 141
Idowu M.A., Bown L., Zhelev. A new method for identifying a data-consistent self-reconfigurable predictive bio-network model of the cell cycle based on time series data and its application in cancer systems biology. Cancer Res 2012 vol 72(8) p 4921
Khalil HS, Tummala H, Hupp TR, Zhelev N. Pharmacological inhibition of ATM by KU55933 stimulates ATM transcription Exp. Biol. Med 2012 vol 237(6) p 622
Mustaffa M, Zhelev N. You cannot always win: molecular bases of the resistance of picornavirusesto WIN compounds. Biotech & Biotech Eq. 2012 vol 26(2) p 2826
Zhelev N. Man of Science: Celebrating Professor Sir David Lane’s 60th anniversary. Biodiscovery 2012 vol 1, 3
Khalil HS, Petkova R, Zhelev N. Differential genetic advantages in youth and in aging, or how to die healthy. Biotech & Biotech Eq 2012 vol 26(1) p 2703
Petkova R, Tummala H, Zhelev N. Nothing in excess – lessons learned from the expression of high-mobility group proteins type A in non-cancer and cancer cells. Biotech & Biotech Eq 2011 vol 25(4) p 2572
Zhelev N. The “golden age” of biotechnology in Europe. Biotech & Biotech Eq 2011 vol 25(4) p 2688
Tummala H; Fleming S; Hocking PM; Ali M; Inglehearn CF; Zhelev N; Lester DH. Mutant GNB3 gene mediates aberrant signalling events leading to renal and visual anomalies in rge chickens. PLoS 2011 vol 6 (8) p 21156
Tummala H, Khalil HS, Nikolova E, Mitev V, Zhelev N. Cell-based nanosensors for systems biology research and drug development. Curr Opin Biotech 2011 vol 22(1) p 25
Tummala H, Khalil HS, Zhelev N. Repair, abort, ignore? Strategies for dealing with UV damage. Biotech & Biotech Eq. 2011 vol 25(3) p 2443
Clyde RG, Tummala H, Khalil HS, Goszcz K, Lucka I, Tupone MG, Zwirek M, Cavicchi L, Vallatur J, Stoyanova V, Mitev V, Zhelev N (2011). A novel quantitative systems biology approach to cancer research and treatment. Curr Opin Biotech 2011 vol 22(1) p 58
Khalil HS, Tummala H, Omoboye AO, Zhelev N. Novel insights of ATM regulation and its potential as a target for therapeutic intervention in cancer Curr Opin Biotech 2011 vol 22(1) p 115
Idowu MA, Goltsov A, Khalil HS, Tummala H, Zhelev N, Bown J. Cancer research and personalized medicine: a new approach to modeling time-series data using analytical methods and Half systems. Curr Opin Biotech 2011 vol 22(1) p 59
Stoyanova V, Zhelev N, Ghenev E, Bosheva M.Assessment of left ventricular structure and function in rats subjected to pressure-overload hypertrophy in time. Kardiol Pol 2009 ;vol 67(1) p 2
M. Peter Fischer, Nikolai Zhelev. Antennapedia homeodomain helix 3 derived translocation vectors. EP1135410 B1; Dec 31, 2008
Stoyanova V, Zhelev N. Alterations in protein P53 expression during the development of pressure overload-induced left ventricular hypertrophy in rats. Biotechnol. & Biotechnol Eq 2008 vol. 22 (4) p 977
Atanasova G, Isaeva A, Zhelev N, Poumay Y, V Mitev. Effect of the CDK-inhibitor CYC202 on p38MAPK, ERK ½ , c-Myc activities and proliferation of papillomavirus type 16 E6E7-transformed keratinocytes. Oncology Reports 2007 vol. 18, (4) p 999
Nikolova E, Mitev V, Zhelev N, Deroanne CF, Poumay Y. The small Rho GTPase Rac1 controls normal human dermal fibroblasts proliferation with phosphorylation of the oncoprotein c-myc. Biochem Biophys Res Commun 2007 vol 359: p 834
Neychev VK, Nikolova E, Zhelev N, Mitev VI. Saponins from Tribulus terrestris L are less toxic for normal human fibroblasts than for many cancer lines: influence on apoptosis and proliferation. Experimental Biology and Medicine 2007 vol 232 (1) p 126
Peter M. Fischer, Nikolai Zhelev, Shudong Wang. Forms of membrane transport vector penetratin; a membrane translocation peptide carrier moiety of given amino acid sequence; use in the improved delivery of therapeutic agents into target cells. US7153931 B1; Dec 26, 2006
Miteva L, Zhelev N, Mitev V. Molecular targets for hyperproliferating skin diseases. Allergy Hypersensitivity Asthma 2006 vol 4 p 2
Clyde R.G,, Bown J.L, Hupp T.R, Zhelev N, Crawford J.W. The role of modeling in identifying drug targets for diseases of the cell cycle. J. R. Soc Interface 2006 vol. 3(10) p 617
Peter Martin Fischer, Nikolai Zhelev. Drug delivery; peptide carrier is linked via oligonucleotides, nucleotides, proteins, or peptides to drugs (anticancer agents, antitumor agents- paclitaxel and/or popdphyllotoxin). US7101967 B2; Sep 5, 2006
Stoyanova V, Dobreva B, Ghenev E, Zhelev N. In vivo assessment of left ventricular hypertrophy in rats: necropsy validation. Biotechnol. & Biotechnol Eq 2006 vol. 20 (2) p 12
Wang S, Zhelev N.Z, Duff S, Fischer P.M. Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. Bioorg Med Chem Lett. 2006 vol. 16(10) p 2628
Peter M. Fischer, Shudong Wang, Nikolai Zhelev. Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. US6992169 B2; Jan 31, 2006
Zhelev N., Barudov S. Laser light scattering applications in biotechnology. Biotechnol & Biotechnol Eq 2005 vol. 19 (3) p 3
Stoyanova V.K, Zhelev N.Z., Yanev I.B, Ghenev E.D, Nachev C.K Time course and progression of pressure overload-induced cardiac hypertrophy in rats. Folia Med 2005 vol. 47(2) p 52
Atanasova G, Jans R, Zhelev N, Mitev V, Poumay Y. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes. Biochem Pharmacol. 2005 vol. 70(6) p 824
Zhelev N, Neichev V. The significance of the type quality and form of the carbohydrate intake for the optimum re-synthesis of the muscular glycogen during the first restoration phase. Medicine and Sport 2005 vol. 2 p 32
Zhang GJ., Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg D.S, Shapiro G, Kaelin W.G Jr. Bioluminescent imaging of Cdk2 inhibition in vivo. Nature Medicine 2004 vol. 10(6) p 643
Neichev V.K, Nikolova E.M, Zhelev N, Mitev V.I. Investigation of the influence of Tribulus terrestris extract on proliferation of normal human skin fibroblasts. Oncologos 2004 vol. 1 p 89
Atanasova G, Jans R, Zhelev N, Mitev V, Poumay Y.G.. Cell cycle arrest by CDK inhibitor CYC202 (R-roscovitine) in normal human keratinocytes is followed by induction of p38 MAPK phosphorylation and subsequent involucrin expression. on the physiology of cultured human keratinocytes. Journal of Investigative Dermatology. 2004 vol. 122(3) p 95
Isaeva A.P. Petrov S, Zhelev N. Effect of polyamines on the proliferation of normal and cancer cells. Isaeva A.P, Petrov S, Zhelev N. Effect of polyamines on proliferation of normal and tumour cells Oncologos 2004 vol. 1 p 83
Sarek J, Klinot J, Dzubak P, Klinotova E, Noskova V, Krecek V, Korinkova G, Thomson J.O, Janostakova A, Wang S, Parsons S, Fischer P.M, Zhelev N.Z, Hajduch M. New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships J Med Chem 2003 vol. 46(25) p 5402
Peter M. Fischer, Shudong Wang, Nikolai Zhelev. Carrier based drug delivery system. US6472507 B1; Oct 29, 2002
McClue S.J, Blake D, Clarke R, Cowan A, Cummings L, Fischer P.M, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002 vol. 102(5) p 463
Zheleva D.I., McInnes C., Gavine A.L.., Zhelev N.Z., Fischer P.M., Lane D.P. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res 2002 vol. 60(5) p 257
McClue S., Fischer P.M, Blake D, Clarke R, Duff S., Krauss E., Cummings L, Stewart K, Melville J, Wang S, Zhelev N, Zheleva D. Studies on the mechanism of action of CYC202 (R-roscovitine). Proc AACR 2002 vol. 43 p 666
Wang S., Blake D., Clarke R., Duff S., McClue S., McInnes C., Melville J., Stewart K., Taylor P., Westwood R., Wood G., Wu S.., Zhelev N.Z.; Zheleva D. I.; Walkinshaw M., Lane D. P.; Fischer P. M. 4-Heteroaryl-2-phenylamino-pyrimidines, a new class of CDK2 inhibitors: Discovery, optimization, and antiproliferative activity in vitro and in vivo. Proc AACR 2002 vol. 43 p 848
Fischer P.M., Zheleva D.I., McInnes C., Gavine A.L., Zhelev N.Z., Lane D.P. Peptide inhibitors of cyclin-dependent kinases derived from p21(WAF1): delineation and structural insight into their interactions with cyclin A. Clin Cancer Res. 2001 vol 7 (11) p 3821
Whittaker, S., Walton, M., Kelland, L., Garrett, M., Zhelev, N. and Workman, P. Rb Phorphorylation as a pharmacodynamic marker of Roscovitine (CYC202) activity in vitro and in vivo. Proc AACR 2001 vol 42, p 926.
Kovarova H., Hajduch M., Korinkova G., Halada P., Krupickova S., Gouldsworthy A. Zhelev N.Z and Strnad M. Proteomics approach in classifying the biochemical basis of the anti-cancer activity of a new olomoucine-derived synthetic cyclin dependent kinase inhibitor, bohemine. Electrophoresis 2000 vol. 21, p 3757.
Zheleva D. I., Zhelev N. Z., Fischer P. M., Duff S.V., Warbrick E, Blake D. G., and Lane, D. P A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA - affinity, stoichiometry, and thermodynamics. Biochemistry 2000 vol.39(25), p 7388.
Zheleva D. I., Fischer P.M., Zhelev N. Z., Melville J. E., Gavine A-L., and Lane D. P. Design of cell-permeable peptides inhibitors of cyclin D1/ CDK4 complex. M Nature Biotech Sh R 2000 vol. 11, p 25
Zhelev N. Z., Zheleva D. I., Fischer P.M., Duff S.V., and Lane D. P. Growth inhibitory effect of peptides derived from the C-terminal domain of P21waf is mediated by cyclin D1/CDK4 inhibition: PCNA binding is not essential. M Nature Biotech Sh R 2000) vol. 11, p 22
Zheleva D. I., Zhelev N. Z., Fischer P.M., Duff S.V., Chan W., Gouldsworthy A. M., and Lane D. P. Affinity capture method for identification of peptide inhibitors of cyclin dependent kinases. M Nature Biotech Sh R 2000 vol. 11, p 83
Fischer P. M., Zhelev N. Z., Wang S., Melville, J. E., Fåhraeus R., and Lane, D. P. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J. Peptide Res. 2000 vol. 55 (2), p 163 .
Fischer P. M., Zhelev N. Z., Fåhraeus R., Ball K. L., Warbrick E., and Lane, D. P. Intracellular delivery of cell-cycle inhibitor peptides by Penetratin, a 16-residue peptide from the Antennapedia homeoprotein. In Peptides 1998, (Bajusz S., and Hudecz F., Eds.), p 700.
Zhelev N. Zh., Barratt M. J. and Mahadevan L. C. Use of reversed-phase high-performance liquid chromatography on polystyrene-divinylbenzene columns for the rapid separation and purification of acid-soluble nuclear proteins. J Chromatogr. 1997. vol. 763, p 65
Zhelev N.Zh., Buckle R., Snyder D. and Marsh P. Studying of protein-DNA binding by dynamic light scattering. Cell Mol Biol L 1996 vol. 1(2), p 199.
Zatsepina O. V., Zhelev N. Zh. and Jordan E. G. Immunolocalization of nucleolar protein B23 in mitotic centrosomes. Mol Biol 1995 vol. 29(6), p1359
Barratt M. J., Hazzalin C. A., Zhelev N. Zh. and Mahadevan L. C. A mitogen- and anisomycin- stimulated kinase phosphorylates HMG14 in its basic amino-terminal domain in vivo and on isolated mononucleosomes. EMBO J 1994 vol. 13(19), p 4524.
Kardalinou E., Zhelev N. Zh., Hazzalin C. A. and Mahadevan L. C. Anisomycin and rapamycin define an area upstream of p70/85 S6K containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos, c-jun induction. Mol Cell Biol 1994 vol. 14(2), p 1066
Zhelev N. Zh., Kardalinou, E., Hazzalin C. A., Cano E., Barratt M. J. and Mahadevan L.C. Signalling to chromatin and the superinduction of proto-oncogenes. Biochem Soc Trans 1993 vol. 21, p 907.
Kicheva, M. I.; Zhelev, N. Zh.; Popova, L. P. Effect of water stress on protein synthesis in two wheat cultivars differing in drought tolerance. C R Acad Sci Bulg 1993 vol. 46(3), p 95.
Miteva T. S., Zhelev N. Zh. and Popova L. P. Effect of salinity on the synthesis of ribulose-1,5,-bisphosphate carboxylase/oxygenase in barley leaves. J Plant Physiol 1992 vol. 140(1), p 46.
Zhelev N. Zh., Bachvarova N. N. and Chelibonova-Lorer H. O-Glycosylation of total cellular proteins during the cell cycle. C R Acad Sci Bulg 1992 vol. 45(1), p 73.
Zhelev, N.Zh., Todorov, I.T. Philipova, R.N., and Hadjiolov, A.A. Phosphorylation-related accumulation of the 125K nuclear matrix protein mitotin in human mitotic cells. J Cell Sci 1990 vol. 95, p 59
Pironcheva, G.L., Semionov, E.P., and Zhelev, N.Zh. Heat shock reaction in cells. Adv Molec Biol 1989 vol. 8, p 73.
Zhelev, N.Zh., Philipova, R.N., Todorov, I.T. and Hadjiolov, A.A. Differential stability of the 125 kDa nuclear matrix protein mitotin in the cell cycle. C. R. Acad. Sci. Bulg. 1989 vol. 42(11), p 103.
Pironcheva, G., Zhelev, N.Zh., and Russev, G. Isolation of U5 snRNP particles. Cytobios 1988 vol. 56, p39.
Todorov, I.T., Philipova, R.N., Zhelev, N.Zh. and Hadjiolov, A.A. Changes in a nuclear matrix antigen during the cell cycle: interphase and mitotic cells. Biol Cell 1988 vol. 62, p 105.
Philipova, R. N., Zhelev, N. Zh., Todorov, I. T. and Hadjiolov, A. A. Monoclonal antibody against a nuclear matrix antigen in proliferating cell. Biol Cell 1987 vol.60, p 1.
Todorov, I. T., Philipova, R. N., Zhelev, N. Zh. and Hadjiolov, A. A. Monoclonal antibody to a nuclear antigen of human B-lymphoblastoid cells. Cell Biol Int Rep 1987 vol.11(3), p 181
My group has received research funding from the Scottish Enterprise, Royal Society of Edinburgh, Socrates Erasmus, Carnegie Trust, the UK Government, Medical Research Scotland and Northwood Trust.
Fellow of the Royal Society of Biology (UK)
Fellow of the Institute of Biology (UK)
Full Member of the Bulgarian National Academy of Medicine
Doctor Honoris Causa (Medical University Plovdiv)Professional Activities
2015 - present Editorial Board, Journal of Molecular Medicine
2015 - present Editorial Board, Journal of Basic Medical Sciences
2014 - present President, European BioDiscovery Federation
2014 - present Editorial Board, EC Cancer Journal
2014 - present Editorial Board, Journal of Molecular Engineering & Systems Biology
2012 - present Managing Editor, BioDiscovery
2011 - present Visiting Professor, Fujian University of Traditional Chinese Medicine
2008 - present Reviewer of research grant proposals for Medical Research Council (MRC), UK; National Centre for Research and Development (NCBR), Poland; National Science Fund (NSF), Bulgaria; The Cargegie Trust, UK.
2005 - present Editor, Medicine and Sport
2005 - present Editorial Board, Biotechnology and Biotechnological Equipment
2004 - present Editor, Zone4science
2003 - present Visiting Professor, Fujian Medical University
2003 - 2005 Honorary Professor, Xiamen Medical University
2003 - present Honorary Professor, Technical University of Varna
2002 - 2004 Visiting Professor, Wuhan Institute of Botany, Chinese Academy of Sciences
2002 - present Editor, Technology in Cancer Research and Treatment
1992 - present Journal Referee for: Cytobios, Adv. Molec. Biol, J. Cell Sci, Cell Biol. Int. Rep, Biol. Cell, C. R. Acad. Sci. Bulg, Oncologos, Medicine and Sport, Biotechnol. & Biotechnol. Eq, Zone4science, Technology in Cancer Research and Treatment, Cancer Research Frontiers, BioDiscovery, Advances in Biology, Biotechnology and Genetics, International Journal of Cardiology (IJC) Heart & Vasculature, Toxins.Others
2003 – 2012 Honorary Consul General for Bulgaria in Scotland
2007 - 2013 Chair, Slavic and Eastern European Institute, Scotland